drugset / Trial / NCT00221845

Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients

NCT00221845

RandomizedParallel-groupOpen-labelTreatment

Summary

In children with chronic kidney disease, progression to end-stage renal failure is associated with high patient morbidity and poor quality of life. In adults, inhibition of the renin angiotensin system (RAS) slows down the rate of renal failure progression. This concept is as yet unproven in children, in whom chronic renal failure (CRF) is more commonly due to hypo/dysplastic malformations than to acquired glomerulopathies as typical for adult chronic kidney disease. The current project aims at assessing the genetic and molecular mechanisms and cardiovascular consequences of progressive CRF and to develop a strategy of pharmacological renoprotection in children.

Timeline

Start
1998-01
Primary completion
2007-07
Completion
2010-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramipril Small molecule 6 mg/m2
Background Telmisartan Other / unclassified 50 mg/m2